InvestorsHub Logo

GD

Followers 25
Posts 863
Boards Moderated 0
Alias Born 07/12/2002

GD

Re: None

Friday, 02/05/2021 9:18:45 AM

Friday, February 05, 2021 9:18:45 AM

Post# of 43784
AZN's failed Phase III Open Label Study of MEDI 4736 With/Without
Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic
Head and Neck Cancer (KESTREL) timeline:

The trial hit the final event on July 6th, results' PR today...
The trial enrolled 823 patients at more than 200 sites
in 23 countries, one primary endpoint, 28 secondary endpoints
and 8 other endpoints....

It is time for Geert to PR the data, IMO.

https://www.clinicaltrials.gov/ct2/show/NCT02551159?term=Imfinzi++HNSCC&draw=4&rank=29
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News